Intellia Therapeutics Inc

NTLA remains entrenched in a pronounced downtrend, with price trading well below its major moving averages and having broken key support. Stage 4 distribution and bearish EMA alignment confirm medium-term skew to the downside, while short-term weakness and failed rallies into the 9/20 EMA and 50 SMA zones align timing for immediate downside participation. Execution is recommended now on any bounce toward those resistance areas for rejection and continuation.

• ↑Lombosi Phase 3 data showed an 87% reduction in mean monthly attacks, with 62% of patients attack-free
• ↑Intellia held $628.4M cash as of Q2 2026, supporting R&D into at least 2028
• ↓Q2 2026 net loss was $106.6M, up from $101.3M year-over-year